<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627689</url>
  </required_header>
  <id_info>
    <org_study_id>Molekule-052018</org_study_id>
    <nct_id>NCT03627689</nct_id>
  </id_info>
  <brief_title>Molekule for Allergic Rhinitis/Asthma</brief_title>
  <official_title>Molekule for Allergic Rhinitis/Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molekule</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molekule</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exposure to airborne allergens and pollutants is linked to symptom severity of allergies,
      asthma and other respiratory problems. In this study an air purifier using
      photo-electrochemical oxidation technology (PECO) will be used in the home environment of
      study participants. The investigator will assess the reduction of symptoms from allergic
      rhinitis/conjunctivitis and asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the efficacy of the portable PECO air purifier in
      reducing symptoms from allergic rhinitis and asthma. Using a randomized, double blinded
      placebo, controlled trial we will be then able to assess if there are any changes after the
      use of the PECO air purifier after completing an initial baseline survey &amp; comparing to the
      exit survey. This is a double-blind study, which means that neither the participant nor the
      investigator knows which device is being used until after the trial is over.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accural
  </why_stopped>
  <start_date type="Actual">July 13, 2018</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Control of Allergic Rhinitis and Asthma Test (CARAT) score</measure>
    <time_frame>4 weeks</time_frame>
    <description>CARAT will measure the change in control scores of respiratory allergies and asthma.
Scale 0 (Worse control of allergy and asthma) to 30 (Best control of allergy and asthma). The higher score the better control of allergy and asthma.
There are 10 individual questions, scoring from 0-3.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Asthma</condition>
  <condition>Allergic Rhinitis</condition>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Active air purifier arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active portable air purifier for 1 month at bedside</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham air purifier arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo portable air purifier for 1 month at bedside</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active air purifier in respiratory allergies/asthma</intervention_name>
    <description>Continuous use of air purifier to improve allergies and asthma control</description>
    <arm_group_label>Active air purifier arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham air purifier</intervention_name>
    <description>control arm</description>
    <arm_group_label>Sham air purifier arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic allergic rhinitis and/or conjunctivitis by history

          2. History of adult asthma requiring medications now or in the past

          3. Age â‰¥18

          4. CARAT score less than 24

        Exclusion Criteria:

          1. Participant is &lt;18 years-old

          2. Use of systemic corticosteroids within 14 days of study initiation

          3. Treatment with biologic agents or allergen immunotherapy

          4. Treatment with other immunomodulators (cyclosporine, azathioprine, hydroxychloroquine,
             etc)

          5. Sensitive to fan sound or blue/purple light at night time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikhil G Rao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Molekule</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Molekule</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>environmental intervention</keyword>
  <keyword>allergies</keyword>
  <keyword>air purifier</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03627689/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

